Table 2 miRNA loci localized in CNV regions validated by multiple overlapping CNVs
From: Copy number variation of microRNA genes in the human genome
miRNAs localized in 'DGV-deposited' CNV regions validated by multiple overlapping CNVs | |||||||
|---|---|---|---|---|---|---|---|
miRNA ID | miRNA position | dupl. | minimal CNV region | # CNVs | functional relevance | expression (mimiRNA/[18]) | conservation |
mir-1977 | chr1:556050-556128 | chrM | chr1:554340-569354 | 6 | Â | not reported/NA | primates |
mir-149 | chr2:241044091-241044179 | Â | chr2:241039698-241051687 | 6 | 3) downregulated in squamous cell carcinoma of the tongue [44] | in multiple tissues/high | vertebrates |
mir-566 | chr3:50185763-50185856 | Â | chr3:50173490-50214015 | 7 | Â | in several tissues/absent | primates |
mir-1324 | chr3:75762604-75762699 | Â | chr3:75761737-75839337 | 6 | Â | not reported/NA | primates |
mir-570 | chr3:196911452-196911548 | Â | chr3:196905807-196918722 | 9 | Â | in several tissues/absent | primates |
mir-548i-2 | chr4:9166887-9167035 | Â | chr4:9152768-9182838 | 9 | Â | not reported/NA | primates |
mir-548i-3 | chr8:7983873-7984021 | Â | chr8:7965981-8024983 | 14 | Â | not reported/NA | primates |
mir-383 | chr8:14755318-14755390 | Â | chr8:14741501-14763659 | 8 | 4) downregulated in non-obstructive azoospermia [39] | in multiple tissues/absent | vertebrates |
mir-661 | chr8:145091347-145091435 | Â | chr8:145090343-145104971 | 8 | 5) downregulates the expression of metastatic tumor antigen 1 (MTA1), inhibits the motility, invasiveness, anchorage-independent growth, and tumorigenicity of cancer cells [48] | in several tissues (mostly ovary and ovary-derived cancers)/absent | primates |
mir-1299 | chr9:68292059-68292141 | Â | chr9:68291272-68298205 | 7 | Â | not reported/NA | primates |
mir-126 | chr9:138684875-138684959 | Â | chr9:138680837-138688363 | 14 | 6) suppresses cell growth in colon cancer [43]; downregulates HOXA9, playing a role in the development of many organs and often upregulated in myeloid leukemias [37]; regulates angiogenic signaling and vascular integrity [38]; overexpressed in ALL and AML [42] | high, in multiple tissues/high | vertebrates |
mir-202 | chr10:134911006-134911115 | Â | chr10:134903011-134918923 | 10 | Â | in several tissues/absent | vertebrates |
mir-1268 | chr15:20014593-20014644 | Â | chr15:19975453-20046356 | 37 | 1) see Table 1 | not reported/NA | primates |
mir-1233 | chr15:32461562-32461643 | chr15 | chr15:32461525-32469857 | 9 | 1) see Table 1 | not reported/NA | primates |
mir-1233 | chr15:32607783-32607864 | chr15 | chr15:32599966-32615283 | 17 | 1) see Table 1 | not reported/NA | primates |
mir-662 | chr16:760184-760278 | Â | chr16:750040-764098 | 6 | Â | in several tissues/absent | primates |
mir-1972 | chr16:68621750-68621826 | chr11 | chr16:68621490-68653097 | 6 | Â | not reported/NA | primates |
mir-142 | chr17:53763592-53763678 | Â | chr17:53751608-53767652 | 11 | 7) increased expression correlates with rejection of organ transplants [40]; overexpressed in pre-B-ALL patients [46]; potentially involved in the development of blood cancer or brain tumors [45] | high, in multiple tissues/absent | vertebrates |
mir-1270 | chr19:20371080-20371162 | Â | chr19:20370872-20383238 | 9 | Â | not reported/NA | primates |
mir-663 | chr20:26136822-26136914 | Â | chr20:26136626-26139184 | 6 | Â | in several tissues/NA | primates |
mir-650 | chr22:21495270-21495365 | Â | chr22:21494381-21502189 | 38 | 1) see Table 1 | in several tissues/high | primates |
mir-514-2 | chrX:146171153-146171240 | Â | chrX:146168796-146174575 | 6 | Â | in several tissues/NA | mammals |
mir-514-3 | chrX:146173851-146173938 | Â | chrX:146168796-146174575 | 6 | Â | in several tissues/NA | mammals |